M.D., Ph.D. Professor Motohiro Nonaka
The molecular constituents of living organisms, including nucleic acids, proteins, and glycans, exhibit abundant diversity in both structure and function. In our laboratory, we aim to efficiently identify key sequences from libraries of diverse molecular patterns, such as peptides and antibodies. Thus far, our studies have centered on identifying biomarkers for refractory diseases and developing novel antibody modalities to reduce immunogenicity. The outcomes of this research will contribute to the progression of personalized medicine in the future.
Research and Education
Thus far, we have been focusing a system that comprehensively identifying peptide sequences binding to target molecules by combining phage display with next-generation sequencing technologies. Currently, we are addressing two main research projects:
1. Development of novel diagnostic and therapeutic strategies for refractory diseases: We are engaged in the development of novel disease biomarkers for refractory diseases such as cancer, allergies, and autoimmune diseases. Additionally, we are pursuing the development of mirror-image antibodies as pharmaceutical modalities with little immunogenicity.
2. Development of methods for controlling glycan function: Glycans are implicated in the onset and progression of nearly all diseases. In our laboratory, we are conducting research to control the function of disease-related glycans by screening and chemically synthesizing glycan-mimetic peptides, which can be administered externally to cells or organisms.
Through our daily research efforts, we aspire to share the joy of standing at the forefront of science and contributing to society based on the achievements derived from our work.
 |
| List of laboratory projects with a focus on the application of phage display technology. |
Publications
- Higashi, K., Oda, S., Fujii, M., Nishida, F., Matsumoto, H., Morise, J., Oka, S., and Nonaka, M. (2023) Construction of a T7 phage random peptide library by combining seamless cloning with in vitro translation. J. Biochem. 175, 85–93
- Aoki, K., Manabe, A., Kimura, H., Katoh, Y., Inuki, S., Ohno, H., Nonaka, M., and Oishi, S. (2023) Mirror-Image Single-Domain Antibody for a Novel Nonimmunogenic Drug Scaffold. Bioconjug. Chem. 34, 2055–2065
- Iwamoto, N., Sato, Y., Manabe, A., Inuki, S., Ohno, H., Nonaka, M., and Oishi, S. (2023) Design and Synthesis of Monobody Variants with Low Immunogenicity. ACS Med. Chem. Lett. 14, 1596–1601
- Nonaka, M., Mabashi-Asazuma, H., Jarvis, D. L., Yamasaki, K., Akama, T. O., Nagaoka, M., Sasai, T., Kimura-Takagi, I., Suwa, Y., Yaegashi, T., Huang, C.-T., Nishizawa-Harada, C., and Fukuda, M. N. (2021) Development of an orally-administrable tumor vasculature-targeting therapeutic using annexin A1-binding D-peptides. PLoS One. 16, e0241157
- Nonaka, M., Suzuki-Anekoji, M., Nakayama, J., Mabashi-Asazuma, H., Jarvis, D. L., Yeh, J.-C., Yamasaki, K., Akama, T. O., Huang, C.-T., Campos, A. R., Nagaoka, M., Sasai, T., Kimura-Takagi, I., Suwa, Y., Yaegashi, T., Shibata, T. K., Sugihara, K., Nishizawa-Harada, C., Fukuda, M., and Fukuda, M. N. (2020) Overcoming the blood-brain barrier by Annexin A1-binding peptide to target brain tumours. Br. J. Cancer. 123, 1633–1643
Laboratory
Professor：Motohiro Nonaka, Ph.D.
TEL: 075-751-3959
e-mail: nonaka.motohiro.4r@kyoto-u.ac.jp
https://nonaka-lab.hs.med.kyoto-u.ac.jp/en/